2 completed, 1 active not recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Proteus Infections: new trials by email Literature Review of Proteus Infections trials Research Report on Proteus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006) Miransertib - PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 60 | 2021-11-02 | 2025-02-07 |
| Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients ECMPS-IEM - Detection Accuracy, Patient Compliance | Phase 2 | Completed | Novartis Pharmaceuticals | 30 | 2011-05-10 | 2017-02-23 |
| Community - Associated Extended-spectrum Beta-lactamases (ESBL) Infection, E Coli Infections | Completed | University of Pittsburgh | 100 | 2006-08-01 | 2015-12-17 |
Congenital Abnormalities (1) · Escherichia coli Infections (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Infections (1) · Klebsiella Infections (1) · Patient Compliance (1)
Bacterial Infections (3) · Bacterial Infections and Mycoses (3) · Enterobacteriaceae Infections (3) · Gram-Negative Bacterial Infections (3) · Infections (2) · Behavior (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Health Behavior (1) · Heredodegenerative Disorders, Nervous System (1) · Nervous System Diseases (1) · Nervous System Malformations (1) · Neurodegenerative Diseases (1) · Neuromuscular Diseases (1) · Patient Acceptance of Health Care (1)
Miransertib (1)
Merck Sharp & Dohme LLC (1) · Novartis Pharmaceuticals (1) · University of Pittsburgh (1)
United States (2) · Australia (1) · Brazil (1) · Italy (1) · Switzerland (1) · United Kingdom (1)
Yohei Doi, MD (1)